Navigation Links
Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
Date:4/28/2008

HAYWARD, Calif. and ST. LOUIS, April 28 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) and Mendel Biotechnology, Inc. today announced a collaborative agreement to enhance the development of Mendel's BioEnergy Seeds & Feedstocks business. Under the terms of the agreement, Mendel will benefit from Monsanto's industry-leading expertise in the testing, breeding, and development of crops.

Mendel and Monsanto have worked together on the development of biotechnology traits for more than a decade in many crops, including corn, soy, cotton and canola. In this new collaboration, the two companies will apply Monsanto's expertise in crop testing, breeding and seed production to perennial grass seed varieties Mendel is developing for use in biofuels and other commercial applications.

"Mendel sees a bright future for second generation biofuels. We recognize the need to continue growing our capabilities and expertise to enable us to best serve farmers and refiners with proprietary seed products," said Neal Gutterson, president and chief executive officer of Mendel. "Monsanto is the global leader in the development and commercialization of high-value, sustainable seed products. We are excited to work with Monsanto's outstanding technical team to enhance our ability to create high-performing dedicated energy crops."

"Monsanto has been committed to providing farmers with higher grain yields to help them meet demand for food, feed and fuel," said Steve Padgette, vice president of biotechnology at Monsanto. "This collaboration has the potential to advance discoveries in the next frontier: cellulosic biofuels. It also presents both companies with an opportunity to broaden our understanding of the strengths and potential application
'/>"/>

SOURCE Monsanto Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monsanto Executives to Address Investor Conferences in February
2. National Academy of Sciences Recognizes Monsantos Chief Technology Officer for Development of Agricultural Biotechnology
3. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
4. Monsanto and Devgen Describe New Approach to Insect-Protection
5. Monsanto Company Executives Adopt 10b5-1 Trading Plans
6. Science Magazine Recognizes Monsanto as Top Employer
7. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
8. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
9. Monsanto and Evogene Collaborate on Nitrogen Use Efficiency Research
10. Monsanto Company Signs Share Subscription Agreement With Devgen
11. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Company Cites Important Progress With Needle-free Vaccine Technology and ... Bird Flu ... March 31, 2008, IRVING, Texas, March 31 Carrington,Laboratories, Inc. ... net loss of $9.8 million, or ($0.90) per basic and,diluted share, ...
... Inc. (NYSE: CRY ),(the "Company"), a biomaterials, ... entered into a credit facility with GE Healthcare,Financial ... in revolving,credit for working capital, acquisitions and other ... at which time the outstanding,principal balance will be ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 2CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 3
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2